News | Contrast Media | September 03, 2019

Korean study is first step toward building a national registry to help identify and prevent iodinated contrast media-related hypersensitivity reactions


September 3, 2019 — Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast media are at risk for future reactions, according to a large study published in the journal Radiology.1 Allergic reactions to commonly used computed tomography (CT) contrast media may be prevented by premedicating patients with antihistamines and using a different type of contrast agent.

Iodinated contrast media (ICM) is used in a vast number of CT exams to improve visualization of the areas of the body being studied. Half of the approximately 88 million CT scans conducted each year in the United States include the use of an ICM.

As ICM use is growing, so too is the occurrence of ICM-related hypersensitivity reactions (HSRs). Most symptoms are mild; however, in some cases ICM-related reactions can cause severe, life-threatening allergic reactions. Despite the potential complications, efforts to identify people at risk of an allergic reaction and take steps to mitigate these risks have been inconsistent. In South Korea, for instance, a country where more than 4 million CT scans involving ICM usage are performed each year, there is no registry for ICM-related HSRs.

For the new study, researchers examined ICM use and the value of preventive measures for ICM-related reactions in almost 200,000 patients, average age 59, who received ICM in 2017 at seven participating institutes.

Of the 196,081 patients who received ICM, 1,433 (0.73 percent) experienced HSRs. Most of the events were mild; however, 16.8 percent of the events were classified as moderate to severe. Predictors of reaction included a patient's previous individual history of an ICM-related HSR, hyperthyroidism, drug allergy, asthma and other allergic diseases, and a family history of ICM-related HSRs.

The researchers found that use of antihistamines and switching to an iodinated contrast media with a different safety profile were useful for reducing the recurrence of reactions.

"We wanted to emphasize in our study the importance of premedication and change of iodinated contrast media type as useful preventive measures to prevent recurrent hypersensitivity reaction," said study co-lead author Min Jae Cha, M.D., from the Department of Radiology at Chung-Ang University Hospital in Seoul. "Hypersensitivity reactions to iodinated contrast media are not rare, but many of them are still preventable."

The link between family history as well as previous individual history of HSRs to ICM suggests that some people have a genetic predisposition to a reaction, Cha said. The researchers are studying this potential genetic susceptibility with an eye toward developing a better understanding of HSR-related genetic profiles. Susceptibility genes for other conditions such as asthma, allergic rhinitis and atopic dermatitis have been identified, Cha noted.

Even with adequate premedication and the changing of contrast media, up to one-third of patients in the study experienced allergic reactions — a finding that underscores the importance of a nationwide registry for ICM-related HSRs as the basis for establishing a strategy to prevent recurrent HSR.

"We hope that we can establish a systematic nationwide integrated registry for ICM-related HSRs in Korea soon, and our study could be a first step toward that goal," Cha said. "Large-scale and long-term registries involving continuous data collection with standardized protocols will help us unravel all aspects of the contributors to the occurrence and recurrence of hypersensitivity reactions to iodinated contrast media."

For more information: www.pubs.rsna.org/journal/radiology

 

Reference

1. Cha M.J., Kang D.Y., Lee W., et al. Hypersensitivity Reactions to Iodinated Contrast Media: A Multicenter Study of 196,081 Patients. Radiology, published online Sept. 3, 2019. https://doi.org/10.1148/radiol.2019190485


Related Content

News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiology Business

July 25, 2024 — The radiology gender gap is decreasing, but there remains work to be done, according to an editorial ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
Subscribe Now